Denali Therapeutics is a privately held biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, ALS and others. Located in South San Francisco, Denali was founded by Drs. Marc Tessier-Lavigne, Ryan Watts, Alex Schuth and investors who share the vision that recent scientific insights in genetics, biology and translational medicine offer an unprecedented opportunity to discover and develop effective medicines for neurodegenerative disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/26/16 | $130,000,000 | Series B |
Alaska Permanent Fund ARCH Venture Partners Baillie Gifford Fidelity Biosciences Flagship Ventures | undisclosed |
